The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.25
Bid: 19.00
Ask: 19.50
Change: -0.25 (-1.28%)
Spread: 0.50 (2.632%)
Open: 19.50
High: 19.50
Low: 18.50
Prev. Close: 19.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Stocks up ahead of US nonfarm payrolls

Thu, 04th Jan 2024 16:54

(Alliance News) - Stock prices in London closed higher on Thursday, as investors eye the latest US non-farms data.

The FTSE 100 index closed up 40.74 points, 0.5%, at 7,723.07. The FTSE 250 ended up 45.65 points, 0.2%, at 19,372.05, and the AIM All-Share closed up 1.79 points, or 0.2%, at 755.94.

The Cboe UK 100 ended up 0.6% at 771.71, the Cboe UK 250 closed up 0.6% at 16,874.97, and the Cboe Small Companies ended up 0.5% at 14,940.05.

Stocks in New York were higher at the London equities close, with the DJIA up 0.7%, the S&P 500 index up 0.4%, and the Nasdaq Composite up 0.2%.

Since the new year, eyes have been on the US economy and where interest rates may go in 2024.

On Wednesday evening, investors had the minutes from the latest US Federal Reserve meeting, back in December.

At the December meeting, the rate-setting Federal Open Market Committee agreed to hold its benchmark rate steady in a range between 5.25% and 5.5%. Members indicated that they expect three quarter-percentage point cuts by the end of 2024.

"In discussing the policy outlook, participants viewed the policy rate as likely at or near its peak for this tightening cycle, though they noted that the actual policy path will depend on how the economy evolves," the highly anticipated minutes stated.

Officials "reaffirmed that it would be appropriate for policy to remain at a restrictive stance for some time until inflation was clearly moving down sustainably."

On Thursday, focus has been on the health of the US labour market.

The US labour market added more jobs than expected in December, according to a tracker from payroll processing firm ADP.

ADP said sector employment increased by 164,000 jobs in December, picking up from a 101,000 rise in November and ahead of the FXStreet cited consensus of 115,000. The November total of jobs added was revised from 103,000 to 101,000.

Meanwhile, US new jobless claims fell by more than expected in the most recent week.

According to the US Department of Labor, new jobless claims totalled 202,000 in the week ended December 30. This is down from last week's revised level of 220,000. The latest reading came in lower than FXStreet-cited consensus of 216,000.

The data is out ahead of the US nonfarm payrolls Friday.

Meanwhile, in European equities on Thursday, the CAC 40 in Paris and the DAX 40 in Frankfurt both ended up 0.5%.

According to Destatis, Germany's annual inflation picked up to 3.7%, from 3.2% in November. This came in slightly behind FXStreet market consensus of 3.8%.

Capital Economics' Andrew Kenningham commented: "The jump in Germany's headline inflation rate in December came as no surprise as it was driven by energy price subsidies introduced more than a year ago. With core inflation continuing to trend down, it should not affect investors' expectations for the [European Central Bank] to begin cutting interest rates in the coming months."

The pound was quoted at USD1.2696 at the London equities close Thursday, up compared to USD1.2646 at the close on Wednesday. The euro stood at USD1.0961 at the European equities close Thursday, higher against USD1.0915 at the same time on Wednesday. Against the yen, the dollar was trading at JPY144.48, up compared to JPY143.50 late Wednesday.

In the FTSE 100, retailers Next and JD Sports were the best and worst performing blue-chip stocks respectively, after both provided trading updates including the Christmas period.

JD Sports Fashion plummeted 23%, after cutting its profit outlook amid weaker-than-expected sales growth and gross margins.

The retailer said organic revenue was up 6.0% in the 22 weeks that ended December 30 on a constant currency basis from a year earlier, with like-for-like growth of 1.8%. This was slightly behind its expectations. The retailer expects organic revenue growth of around 8% for the year ending February 3.

As a result, it expects to report pretax profit and adjusted items of between GBP915 million and GBP935 million for the financial year. This falls short of market expectations of GBP1.04 billion, which back in September, JD Sports had said it expected to meet.

Next rose 5.5%, on the back of its trading update.

"Clothing retailer Next has set the bar high for the rest of the retail sector by posting a strong trading update this morning," Edison analyst Russell Pointon commented.

In the nine weeks to December 30, the clothing and homewares seller's full price sales were 5.7% higher year-on-year, some GBP38 million better than its previous guidance. It had expected growth of 2.0% year-on-year. The period forms part of its fourth quarter, which concludes on January 27.

The company now expects pretax profit for financial 2024 of GBP905 million, a lift of GBP20 million from its previous outlook, and it would represent a year-on-year increase of 4.0%. Next had initially expected pretax profit of GBP795 million, but it has, now on a number of occasions, lifted its bottom line outlook.

Meanwhile, BP and Shell rose 0.5% and 0.2%, respectively, as oil prices extended their recent upward movements on concerns over the Middle East.

"The region remains a tinder box due to the Israel-Gaza war, and disruption to shipping routes through the Red Sea is also a key factor behind the surge in crude," AJ Bell's investment director Russ Mould explained.

Brent oil was quoted at USD76.60 a barrel at the London equities close Thursday, down from USD78.13 late Wednesday. Over the last week the price has hit highs of USD79.83.

On London's AIM, Angle shares more than doubled to 31.40 pence.

The Surrey-based medical diagnostics provider celebrated "breakthrough results" from its latest blood sample cancer trials would allow it to expand its product sales and pharma services.

Gold was quoted at USD2,0445.01 an ounce at the London equities close Thursday, up against USD2,038.89 at the close on Wednesday.

In Friday's UK corporate calendar, MTI Wireless Edge will hold its extraordinary general meeting regarding proposed grant of options to the directors.

The economic calendar for Friday has eurozone inflation readings at 1000 GMT. Before that, there is the UK Halifax house price index at 0700 GMT.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
4 Apr 2018 03:02

UPDATE 1-Australia's AGL says approached by Alinta to buy coal-fired Liddell plant

* No formal offer received - AGL * Liddell slated to be closed in 2022 * Australia government sought Alinta's interest (Adds fresh Alinta MD quote, April 4 -

Read more
26 Mar 2018 11:35

ANGLE Shares Rise As Pelvic Mass Test Scores High Prediction Rate

LONDON (Alliance News) - Liquid biopsy firm ANGLE PLC shares climbed on Monday as it said results from a study into is pelvic mass triage test showed a high proportion of were

Read more
13 Mar 2018 07:06

EUROPE RESEARCH ROUNDUP-Capital & Counties Properties, Inmarsat, Norsk Hydro

March 13 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Capital & Counties Properties, Inmarsat and Norsk Hydro, on Tuesday. * :

Read more
9 Mar 2018 15:51

Private equity OpCapita buys owner of Rossopomodoro pizza chain

MILAN, March 9 (Reuters) - European private equity firm OpCapita said on Friday it had reached a deal to buy the majority of Sebeto, an Italian restaurant group whose pizza at

Read more
13 Feb 2017 08:55

Angle selected for European cancer ID programme

(ShareCast News) - Medical technology company Angle has been chosen to take part in Cancer-ID, a European consortium to validate blood-based biomarkers for cancer, by providing a number of Parsortix instruments and associated consumables for evaluation. The evaluation phase, which runs until 2020, w

Read more
26 Jan 2017 11:55

Angle Sees Positive Interim Evaluation In Ovarian Cancer Studies

Read more
4 Nov 2016 09:23

Angle Welcomes Supportive Research On Using Parsortix System

Read more
21 Jul 2016 15:03

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
19 Jul 2016 12:56

Angle initiates 200 patient European ovarian cancer study

(ShareCast News) - Medical technology company Angle's European ovarian cancer study has been formally initiated with a first patient recruited. Angle completed the process required to initiate this study, which included optimising the system protocols for the application, development and approval of

Read more
19 Jul 2016 09:17

Angle Recruits First Patient For European Ovarian Cancer Study

Read more
15 Jul 2016 07:37

ANGLE Flags Parsortix System Traction At Manchester Conference

Read more
12 Jun 2016 13:28

Sunday share tips: Purplebricks, Associated British Foods, Angle

(ShareCast News) - Purplebricks Group shares were a 'buy' in the Sunday Times' Inside the City column. Investing in this online estate agency might be a wild ride, with the shares trading for more than 40 times earnings, but some notable names are on the register since its IPO at the end of last yea

Read more
25 May 2016 07:56

ANGLE Signs University Of Manchester Deal, Raises GBP10.2 Million (ALLISS)

Read more
18 Apr 2016 08:48

ANGLE Gets Strong Results From Parsortix Breast Cancer Tests

Read more
21 Mar 2016 14:04

Angle closer to using cassette tech for prostate cancer detection

(ShareCast News) - There was praise for the progress made by Angle on Monday, in its quest to see one of its existing products used as a diagnostic tool for prostate cancer. The AIM-traded company was the subject of a report by equity advisory firm Edison, which said that while the final data was ye

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.